Colombel, J.F., Sandborn, W.J., Reinisch, W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362 (2010), 1383–1395.
D'Haens, G., Baert, F., van Assche, G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371 (2008), 660–667.
Dulai, P.S., Siegel, C.A., Peyrin-Biroulet, L., Anti-tumor necrosis factor-alpha monotherapy versus combination therapy with an immunomodulator in IBD. Gastroenterol Clin North Am 43 (2014), 441–456.
Siegel, C.A., Marden, S.M., Persing, S.M., et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 7 (2009), 874–881.
Torres, J., Boyapati, R.K., Kennedy, N.A., et al. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology 149 (2015), 1716–1730.
Boyapati, R.K., Torres, J., Palmela, C., et al. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease. Cochrane Database Syst Rev, 5, 2018, CD012540.
Louis, E., Mary, J.Y., Vernier-Massouille, G., et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142 (2012), 63–70.e5 quiz e31.
Reenaers, C., Mary, J.Y., Nachury, M., et al. Outcomes 7 years after infliximab withdrawal for patients with Crohn's disease in sustained remission. Clin Gastroenterol Hepatol 16 (2018), 234–243.e2.
